Trial ID | Molecular Weight | Cross-Linked | Production method | Injection technique | Injection regimen |
---|---|---|---|---|---|
Altman, 2004 | High | Yes | Bio-HA | NR | Single 60Â mg/3Â ml injection of IA-HA or saline |
Altman, 2009 | High | No | Bio-HA | Suprapatellar or infrapatellar approach | 3 weekly injections of IA-HA (20Â mg/2Â ml) or saline |
Arden, 2014 | High | Yes | Bio-HA | Lateral midpatellar, lateral upper-patellar or medial | Single 3Â ml injectionof IA-HA (60Â mg/3Â ml) or saline |
Brandt, 2001 | Moderate | No | Bio-HA | NR | 3 weekly injections of IA-HA (2Â ml; 15Â mg/ml) or saline (2Â ml) |
Chevalier, 2010 | High | Yes | ADHA | NR | Single 6Â ml injectionof IA-HA or saline |
Creamer, 1994 | Low | No | ADHA | NR | Single injection of HA (20Â mg/2Â ml) into one knee and saline (2Â ml) into the other |
Day, 2004 | Low | No | ADHA | Lateral or medial approach | 5 weekly injections of 25Â mg/2.5Â ml IA-HA in a phosphate buffered solution or 2.5Â ml vehicle or saline |
DeCaria, 2012 | Low | No | NR | Anteromedial approach | 3 weekly injections of IA-HA (2Â ml of 20Â mg/ml), or saline (1.2Â ml of 0.001Â mg/ml HA) |
Diracoglu, 2009 | High | Yes | ADHA | NR | 3 weekly injections of IA-HA or saline |
Dixon, 1988 | Low | No | ADHA | NR | Up to 11 injections of IA-HA (20Â mg/2Â ml) or placebo (0.2Â mg sodium hyaluronate) |
Henderson, 1994 | Low | No | ADHA | Medial approach | 5 weekly injections of IA-HA (20Â mg/2Â ml) or saline |
Huang, 2011 | Low | No | ADHA | NR | 5 weekly injections of IA-HA (20Â mg/2Â ml) or saline |
Huskisson, 1999 | Low | No | ADHA | NR | 5 weekly injections of IA-HA (20Â mg/2Â ml) or saline |
Jorgensen, 2010 | Low | No | ADHA | Lateral parapatellar approach | 5 weekly injections of IA-HA (20Â mg/2Â ml) or saline |
Karlsson, 2002 | High | Yes | ADHA | NR | 3 weekly injections of IA-HA (Artzal, 2.5Â ml or Synvisc, 2.0Â ml) or saline |
Kotevoglu, 2006 | High | Yes | ADHA | Anterolateral approach | 3 weekly injections of IA-HA or saline |
Lohmander, 1996 | Low | No | ADHA | NR | 5 weekly injections of IA-HA (25Â mg/2.5Â ml) or saline |
Lundsgaard, 2008 | Low | No | ADHA | Lateral midpatellar portal | 4 weekly intra-articular injections of IA-HA 2Â mL (Hyalgan, 10.3Â mg/ml) versus physiological saline 20Â ml (distention) versus physiological saline 2Â ml |
Navarro-Sarabia 2011 | Low | No | Bio-HA | NR | 4 treatment cycles of 5 weekly injections of IA-HA or saline (2.5Â ml) |
Neustadt, 2005 | Moderate | No | Bio-HA | Lateral or medial approach | 4 weekly injections of IA-HA (30Â mg/2Â ml), or 4 arthrocenteses without injection (control) |
Petrella, 2006 | Low | no | ADHA | NR | 3 weekly injections of IA-HA (20Â mg/ml) or saline |
Petrella, 2008 | High | No | ADHA | Medial approach | 3 weekly injections of IA-HA or saline |
Pham, 2004 | NR | NR | NR | NR | 3 weekly injections of IA-HA or saline |
Puhl, 1993 | High | No | ADHA | NR | 5 weekly injections of IA-HA (25Â mg/2.5Â ml) or dilute IA-HA control(0.25Â mg/2.5Â ml HA) |
Scale, 1994 | High | No | ADHA | NR | Two intra-articular injections of IA-HA (2.0Â ml) administered 2Â weeks apart were compared with three intra-articular injections of IA-HA given 1Â week apart vs saline (2.0Â ml) |
Sezgin, 2005 | Moderate | No | Bio-HA | NR | 3 weekly injections of IA-HA (15Â mg/ml) or saline |
Strand, 2012 | High | Yes | ADHA | NR | Single 3Â ml injection of IA-HA (30Â mg/3.0Â ml) or saline |
Tamir, 2001 | High | No | Bio-HA | NR | 5 weekly injections of 20Â mg IA-HA (10Â mg/ml) or saline |
van der Weegen, 2015 | Low | Yes | Bio-HA | NR | 3 weekly injections of IA-HA (15Â mg/ml) or saline |
Wobig, 1998 | High | Yes | ADHA | NR | 3 weekly injections of 2.0Â ml IA-HA or saline |